title: Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone.
abstract: Prostate carcinomas located in the transition zone are suspected to behave differently from the more frequent peripheral zone cancers. In this study, large transition zone prostate cancers were investigated for pathological and clinical features. From 365 consecutive radical prostatectomy specimens, 73 cases were disclosed with tumours larger than 10 cm(3). Of these, 14 were predominantly (>70% tumour area) located in the transition zone. Pathological investigations included a complete histological work-up, immunohistochemistry for p53 and bcl-2, and interphase cytogenetics for chromosomes 7, 8, 17, and X. Despite large tumour volumes and high preoperative prostate specific antigen (PSA)-values, most tumours showed quite favourable pathological features. Only two of these patients suffered from a postoperative PSA-recurrence during a median follow-up of 50 months. For comparison, 36 cases that contained tumours predominantly located in the peripheral zone mostly displayed adverse prognostic signs and 68.8% of these patients suffered from postoperative PSA-recurrence. We conclude that the peculiar pathological and clinical characteristics of large prostate cancers in the transition zone might be important for prognostic considerations.
authors.affiliation: Institute of Pathology, University of Hamburg, Germany. erbersdobler@uke.uni-hamburg.de
authors.forename: A
authors.initials: A
authors.lastname: Erbersdobler
authors.forename: S
authors.initials: S
authors.lastname: Huhle
authors.forename: J
authors.initials: J
authors.lastname: Palisaar
authors.forename: M
authors.initials: M
authors.lastname: Graefen
authors.forename: P
authors.initials: P
authors.lastname: Hammerer
authors.forename: J
authors.initials: J
authors.lastname: Noldus
authors.forename: H
authors.initials: H
authors.lastname: Huland
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D002877:Chromosomes, Human / Q000648:ultrastructure; D018450:Disease Progression; D006801:Humans; D007124:Immunoenzyme Techniques; D017403:In Situ Hybridization; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009363:Neoplasm Proteins / Q000032:analysis; D011379:Prognosis; D011467:Prostate / Q000737:chemistry / Q000648:ultrastructure; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000737:chemistry / Q000473:pathology* / Q000601:surgery; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis; D016159:Tumor Suppressor Protein p53 / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D016159:Tumor Suppressor Protein p53; D017430:Prostate-Specific Antigen